Commentary: The Real-world Convergence of Comparative Effectiveness Research and Risk-Beneft Assessment

  • John J. Doyle


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baghdadi R. FDA considering “super offce” of drug safety within drug center. RPM Report, March 25, 2011; Scholar
  2. 2.
    Eastman P. ODAC backs FDA’s strong stance on need for post-marketing studies on accelerated-approval cancer drugs. Oncology Times. February 11, 2011; Scholar
  3. 3.
    Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative effcacy data at the time of drug approval in the United States. JAMA. 2011;305:1786–1789; Scholar
  4. 4.
    Jenkins J. A United States regulator’s perspective on risk-beneft considerations. FDA presentation, April 23, 2010; Scholar
  5. 5.
    Slotnik J. CMS-FDA proposed premarket parallel review—the devil is in the details. Value-Based Cancer Care;
  6. 6.
    Memorandum of understanding between United States Food and Drug Administration and Centers for Medicare and Medicaid Services. Fed Register. 48699, August 11, 2010; Scholar
  7. 7.
    Chambers JD, Neumann PJ. Listening to Provenge—what a costly cancer treatment says about future Medicare policy. NEJM. May 5, 2011; Scholar
  8. 8.
    Pollack A. Medicare will pay for prostate drug. New York Times, June 30, 2011; Scholar

Copyright information

© Drug Information Association, Inc 2011

Authors and Affiliations

  • John J. Doyle

There are no affiliations available

Personalised recommendations